Best Nasdaq-100 Stocks to Buy in 2026 (AI Analysis)

Gilead Sciences (GILD) offers a compelling investment case, combining a resurgent growth profile, robust margins, and a strong technical uptrend, all supported by positive sentiment and fair valuation. While moderate regulatory and competitive risks persist, the company’s dominant HIV franchise, expanding oncology pipeline, and consistent earnings execution provide a solid foundation for both near- and long-term investors.

Exelon (EXC) offers a compelling risk-adjusted opportunity, combining stable regulated utility growth, attractive valuation, and a bullish technical setup. While moderate financial leverage and regulatory risks persist, the stock's fundamentals, technicals, and relative undervaluation support a positive outlook across most timeframes. Investors seeking income and steady growth may find EXC particularly appealing.

Ross Stores (ROST) presents a compelling long-term investment case with resilient fundamentals, steady growth, and a robust balance sheet, though its premium valuation and overbought technicals suggest short-term caution. While the stock is fairly valued and technically extended, strong earnings, positive sentiment, and durable business advantages support a bullish outlook, especially for medium- and long-term investors. Near-term volatility is possible, but the risk/reward profile remains attractive for those with a 6-24 month horizon.

Linde plc (LIN) stands out as a high-quality, defensive compounder with industry-leading fundamentals, robust profitability, and secular growth tailwinds in clean energy and hydrogen. While the stock trades at a premium valuation, its technical momentum, consistent earnings beats, and strong market position justify a positive outlook across most timeframes. Near-term liquidity and macro risks are present but are outweighed by operational strength and long-term growth prospects.

Cisco Systems (CSCO) offers a compelling investment case with strong fundamentals, robust earnings growth, and a bullish technical setup, supported by positive sentiment and fair valuation. While moderate liquidity and competitive risks exist, the company's leadership in AI infrastructure and recurring revenues provide meaningful upside for medium- and long-term investors. Near-term, a breakout or pullback entry is favored, with the long-term outlook underpinned by sustainable growth drivers.

Dexcom (DXCM) offers a compelling long-term growth story driven by industry leadership in continuous glucose monitoring, robust fundamentals, and strong sentiment, though short-term technicals suggest a neutral stance. The stock is fairly valued relative to its growth prospects, with analyst targets indicating double-digit upside. Risks are moderate and manageable, making DXCM a strong candidate for long-term investors and a potential buy on near-term pullbacks.